The Freedom® portable driver that powers the SynCardia temporary Total Artificial Heart, the world’s first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, has been named one of four finalists for the 2014 Edison Awards’ devices section in the science/medical category.
Desert Angels portfolio company Calimmune is mentioned is highlighted in a PBS NewsHour Health broadcast as a company at the forefront of gene therapy treatment for HIV patients.
For video and more: In search of a cure, scientists look for where HIV hides
NuvOx Makes the Transition from the Laboratory to the Clinic and is Pounding the Pavement to Raise $15MM
NuvOx Pharma, a Tucson-based biotech startup, founded in 2008 is metamorphosing from an R&D startup to one that is testing the Company’s nanotechnology therapeutic platform in the clinic.
According to Chief Business Officer, David Wilson, this transition ratchets up the expenses, but clinical trials are the only way to determine the therapeutic potential of the NuvOx platform and to garner the interest of potential collaborators and investors. “With demonstrated proof-of-concept in humans, we are now ready to start discussions with potential corporate partners and institutional investors”, according to Dr. Wilson.
Sialix, Inc., a biotechnology company developing products for the treatment and prevention of cancer, today announced the closing of an oversubscribed $1.2 million tranche of an angel-led financing. Among the investors were several angel investment groups including the Desert Angels.
“Building a biotech company today is challenging, and at this stage we have chosen to maintain a lean structure that can be supported with angel funding. It is terrific and validating to get such strong support from a wide variety of angel groups,” said Jeff Behrens, Sialix’s CEO.
With 161 SynCardia temporary Total Artificial Heartsimplanted in 2013, nearly double the 81 implants performed in 2011, SynCardia Systems, Inc. is on track to exceed 200 implants of the Total Artificial Heart in 2014, the company announced today. “We expect demand to continue to accelerate this year,” says Michael P. Garippa, SynCardia CEO and President.
“The SynCardia Heart saves patients dying of heart failure and the Freedom® portable driver provides patients without hu man hearts a life worth living outside the hospital.” The driver significantly improves the patient’s quality of life and eliminates most in-hospital cost for this portion of the patient’s care, Garippa added.
Despite a significant move to online ads, printed weekly grocery circulars have remained a mainstay of supermarkets, which spent more than $11 billion on newspaper circulars alone last year. A Tucson-based tech startup wants to replace those weekly ads with personalized, digital grocery circulars shoppers can use to get deals on what they buy most via the Web.
Desert Angels portfolio company Recoleta Digital Media got a key boost recently when it was awarded a $250,000 grant as a winner of the Arizona Commerce Authority’s annual Innovation Challenge.
Tucson-based Cancer Prevention Pharmaceuticals Inc. has signed an exclusive licensing agreement with a Swiss drug company for European and Japanese rights to develop and commercialize a gastrointestinal-cancer-prevention drug.
The local Desert Angels portfolio company could get payments of more than $100 million over time for hitting drug development and sales milestones, as part of its agreement with Tillotts Pharma AG, a wholly owned subsidiary of Tokyo-based Zeria Pharmaceutical Co. Ltd., Cancer Prevention Pharmaceuticals said.
Tucson-based SynCardia Systems Inc. has raised another $14 million to bankroll development of its artificial heart and related products. The new financing will help spur development of a new, smaller 50cc version of the approved 70cc SynCardia Total Artificial Heart, the availability of the Freedom portable driver and the use of SynCardia technology as a “destination therapy” for patients who are not transplant candidates, said Michael Garippa, president and CEO of SynCardia.
SynCardia’s Total Artificial Heart is the first and only device approved as a bridge to transplant in the U.S., Europe and Canada.
For more: SynCardia raises $14M to develop heart
The Angel Resource Institute, Silicon Valley Bank and CB Insights released the Q2 2013 Halo Report, a national survey of angel group investment activity, and ranked Desert Angels in the top five for most active angel groups in the United States for Q2.
In 2013, Desert Angels have invested in 17 companies totaling over $4M, mostly in early stage companies. Most recently Desert Angels closed on a $517K sidecar fund which adds to current investments made by the group.
Desert Angels portfolio company Strongwatch is teamed with General Dynamics to compete for a Homeland Security contract for mobile surveillance systems potentially worth $50 million. “It’s a big deal — it’s essentially the first major opportunity for our technology to serve national security on the border,” Strongwatch CEO Powell said.
Strongwatch was one of six companies awarded $250,000 grants under the Arizona Commerce Authority’s Innovation Challenge in June. Last week, Strongwatch won the Small Business Innovation award of the Governor’s Celebration of Innovation, sponsored by the Arizona Commerce Authority and the Arizona Technology Council.